Holen Sie sich die Stockscreener-App
0.513
14.25%
0.064
Schlusskurs vom Vortag:
$0.449
Offen:
$0.4355
24-Stunden-Volumen:
187.89K
Relative Volume:
0.98
Marktkapitalisierung:
$6.46M
Einnahmen:
$123.30K
Nettoeinkommen (Verlust:
$-11.95M
KGV:
-0.3327
EPS:
-1.5421
Netto-Cashflow:
$-12.57M
1W Leistung:
-8.59%
1M Leistung:
-32.57%
6M Leistung:
-40.43%
1J Leistung:
-61.72%
1-Tages-Spanne:
$0.429
$0.5356
1-Wochen-Bereich:
$0.41
$0.5594
52-Wochen-Spanne:
$0.41
$1.49
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.513 | 6.46M | 123.30K | -11.95M | -12.57M | -1.5421 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-14 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
APRE 8-K & SEC FilingsYahoo Finance - Yahoo! Finance Canada
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Atrium Therapeutics Announces $50 Million Private Placement - Yahoo Finance
APRE: Aprea Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Aprea Therapeutics to Present at October Conferences - The Manila Times
Aprea Therapeutics, Inc. (APRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aprea Puts Cancer Drug Pipeline Before Investors - MyChesCo
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials - Clinical Leader
Aprea Therapeutics Inc (APRE:UR): Stock Price, Quote and News - bnnbloomberg.ca
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - marketscreener.com
Aprea Therapeutics Expands Patent Portfolio for Precision Oncology Programs - minichart.com.sg
Aprea Therapeutics reports patent portfolio of 58 patents - Investing.com
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com Canada
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com India
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - manilatimes.net
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com UK
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - marketscreener.com
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - Barchart.com
Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ) - Seeking Alpha
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateEarnings Expansion Phase - vinanet.vn
Aprea (APRE) Stock: Advances 1.19% to $0.64 in the Latest Reading; Market Levels: the Current Price Sits Inside the Supplied Technical Range in the Current UpdateHigh Volume Node - vinanet.vn
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateOne-Time Loss Impact - careplusvn.com
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateEarnings Weakness Phase - dars.gov.et
Aprea (APRE) Q1 2026 Scorecard: EPS Exceeds Its Estimate in the Latest Session; Stock Move: The Market Price Declines 2.61% at the CloseInterim Report - careplusvn.com
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotChandelier Stop - vinanet.vn
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotLow Risk Entry Stocks - dars.gov.et
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotHigh Dividend Factor - www.dars.gov.et
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Signals Disciplined ExecutionEarnings Recovery Stocks - Vinanet
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity - MyChesCo
Aprea Therapeutics (APRE) Edges Higher by 1.34% as Shares Hover Above Key SupportStrangle Setup - vinanet.vn
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Mid Cap Momentum - vinanet.vn
Oppenheimer Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Quote Data - dars.gov.et
Aprea Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
APRE: APR-1051 demonstrates promising early efficacy and safety, driving a biomarker-focused oncology pipeline - TradingView
Aprea Therapeutics advances APR-1051 oncology pipeline progress - TipRanks
Form 8K Aprea Therapeutics Inc For: 12 August - Investing.com India
Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan
Aprea Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Aprea Therapeutics Reports $3.6 Million Q2 Net Loss - Quiver Quantitative
Aprea Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds - Yahoo Finance
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - finance.yahoo.com
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aprea Therapeutics Inc-Aktie (APRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Jan 30 '26 |
Buy |
0.89 |
5,700 |
5,073 |
33,433 |
| Duey Marc | Director |
Dec 10 '25 |
Buy |
1.17 |
21,459 |
25,000 |
256,155 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Dec 10 '25 |
Buy |
1.17 |
5,000 |
5,825 |
27,733 |
5.91%
2.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):